CurcuWIN™ compared to commercially available products in robust trial

Randomized , Double–blind, Cross over design

- N = 12 completed [11 male and 1 female], Age 23.0 ± 2.4 years, 1 African American and 11 Caucasian
- Each subject received all four treatments; acted as their own control
- 7 day washout
- Fasting state
- Interventions & Dose: Standard Curcumin [1800 mg]; Curcuminoids in combination with rhizome essential oils [376 mg]; Curcumin and phosphatidylcholine [376 mg] and CurcuWIN [376 mg]
- Blood Collections: 0, 1, 2, 3, 4, 5, 6, 8, and 12 hours
- Set new standard using statistical model with lower variability and improved accuracy

Jäger R et al. Comparative absorption of curcumin formulations. *Nutr.J* 2014 Jan 24;13(1):11. [Epub ahead of print]

OmniActive HEALTH TECHNOLOGIES

CurcuWIN™

CurcuWIN™ significantly more bioavailable than other commercial formulations



Jäger R et al. Comparative absorption of curcumin formulations. *Nutr.J* 2014 Jan 24;13(1):11.

OmniActive HEALTH TECHNOLOGIES

Curcuwin™

CurcuWIN™ significantly more bioavailable than other commercial formulations



Jäger R et al. Comparative absorption of curcumin formulations. *Nutr.J* 2014 Jan 24;13(1):11.